Urgent.News

What's breaking now, across thousands of outlets.

Tech

Mitsui Chemicals to buy chip materials maker JSR for $11 bln

Mitsui Chemicals to buy chip materials maker JSR for $11 bln

Mitsui Chemicals, Inc. announced on Monday that it has reached an agreement to acquire chip materials maker JSR from JIC Capital for 1.8 trillion yen, or $11.6 billion. The investment will bolster Mitsui's capabilities in chipmaking technology. The venture capital arm of the Development Bank of Japan will contribute an additional 200 billion yen to the deal.

Mitsui believes that the merger will make the combined entity the largest semiconductor materials producer in Japan based on sales. The firm anticipates generating approximately 40 billion yen in additional profit annually by the year 2035.

Mitsui plans to finance the acquisition via a combination of 1.64 trillion yen in bridge loans from its primary banks and a 200 billion yen equity investment from DBJ. However, the company cautioned that its debt-to-core-earnings ratio will temporarily surpass 4.0 following the acquisition. To maintain a favorable credit rating, Mitsui intends to refinance the bridge loan within one year of completing the deal.

Following the news of the acquisition, Mitsui's shares increased by 1.3% on Monday. The stock had previously declined nearly 12% on Friday after Reuters first reported on the potential deal.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Tech

Celltrion’s Steqeyma Recommended for Expanded Pediatric Indications in Europe

Celltrion said on Nov. 9 that its biosimilar Steqeyma (ustekinumab; development code CT-P43), referencing Johnson & Johnson’s Stelara, has received a positive recommendation from the European…

  • European Medicines Agency CHMP recommends Steqeyma for pediatric Crohn's and colitis.
  • Steqeyma already approved for various indications, including adult and child use.
  • Celltrion expanding autoimmune disease portfolio with new biosimilars.

More from Monday 9 November →